CAR NK cells are allogenic, which is defined as taking the cells from a non-related healthy donor rather than the patient themselves. Therefore, CAR NK cells have the potential to be manufactured in advance and stored for off-the-shelf immediate use.
Based on molecular similarities in human and canine diffuse gliomas, researchers have posited that working to cure brain cancer in dogs may lead to improved treatments and even a cure for humans.
Positive results were based on the PROSPER trial, which evaluated the overall survival of enzalutamide plus androgen deprivation therapy versus standard of care.
Capmatinib is an investigational, oral, and selective MET inhibitor, and if approved, it will be the first therapy to specifically target METex14 mutated advanced lung cancer, according to the company.
While KTE-X19 is not yet approved in any country, its Marketing Authorization Application has been validated in the European Union, and its target action date in the United States is August 10, 2020.
Two studies published in The Lancet have developed models to examine what may happen if the World Health Organization commits to a 3-part strategy to end cervical cancer.
Clinical trials are now evaluating the potential combination of PARP inhibitors with immunotherapy or other agents in patients with ovarian cancer.
Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer.
Treatment with niraparib resulted in a 38% reduction in the risk of disease progression or death in the overall study population compared with placebo.
With emerging research from The Sidney Kimmel Cancer Center-Jefferson Health, outcomes in patients with uveal melanoma that has metastasized were shown to significantly improve with changes in treatment.
A study conducted by LSU Health found that by the time recommended screening for colorectal cancer begins, the disease has already spread in a high percentage of patients.
New technique addresses the tendency of most CAR-T therapies to provoke immune responses against healthy tissues in patients.
Not only is cancer control a matter of public health, but its value should be viewed as an investment with considerable human and economic returns, according to a newly released report from the World Health Organization (WHO). Furthermore, although disparities between cancer care in lower- and higher-income countries may seem overwhelming, the report emphasized that they are entirely solvable with effective national cancer control plans.
A combination therapy may counter the resistance to human epidermal growth factor receptor 2 inhibitor neratinib in patients with breast, ovarian, lung, or other cancers.
The study was the first to explore sociodemographic disparities in young adult patients with colorectal cancer.
Two large studies demonstrating patient-reported outcomes showed that quality of life was maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer (CRC) and unresectable hepatocellular carcinoma (HCC). The results were presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California, from January 23-25.
Advances in research and immunotherapy have led to breakthroughs regarding biologics targeting melanoma.
A blood-based screening test using cell-free DNA may be able to identify cancer at earlier stages than what was previously possible, according to research to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco.
Tazemetostat blocks any activity of the EZH2 methyltransferase, which may help keep the cancer cells from further growth.
Pfizer will become the first to launch 3 oncology monoclonal antibody biosimilar treatments to the US market.
The study was the first to examine proton pump inhibitors use in breast cancer survivors.
Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.
The report projects changes in upcoming health care markets, including kidney care, digital health, drug cost transparency, the loneliness epidemic, and the self-care market.
Avapritinib was awarded FDA approval on Jan 9.
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.
Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.
Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.
Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.
The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.
